Tri-xylenyl phosphate (TXP) is a type of organophosphate flame retardant that is used in a variety of applications, including plastics, textiles, and electronics. It is synthesized through a chemical reaction involving xylenol and phosphorus oxychloride. TXP is a colorless, odorless, and viscous liquid that is highly lipophilic, meaning it readily dissolves in fats and oils. This property allows it to effectively migrate from products into the environment and human bodies. TXP has been linked to various health concerns, including developmental neurotoxicity, reproductive toxicity, and endocrine disruption. The widespread use of TXP and its potential adverse effects on human health and the environment have led to significant research efforts to understand its properties, fate, and impacts. Studies are conducted to explore its bioaccumulation, persistence in the environment, and the potential for biomagnification in food chains. Furthermore, researchers are investigating the mechanisms of toxicity and developing safer alternatives to TXP. '
```
tri-xylenyl phosphate: RN given refers to cpd with unspecified methyl-locants [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 19736 |
| SCHEMBL ID | 108984 |
| MeSH ID | M0096207 |
| Synonym |
|---|
| xylenol, phosphate (3:1) |
| tri-dimethyl phenyl phosphate |
| tri-xylenyl phosphate |
| xylyl phosphate |
| dimethylphenol phosphate (3:1) |
| phosflex 179 |
| coalite ntp |
| phosphate, trixylyl |
| hsdb 6094 |
| einecs 246-677-8 |
| trixylenyl phosphate |
| phosphoric acid, trixylyl ester |
| ccris 4891 |
| ivviol-3 |
| 2,4-xylyl phosphate, (c8h9o)3po |
| nsc 78488 |
| hsdb 3908 |
| tri-2,4-xylyl phosphate |
| brn 1895059 |
| reofos 95 |
| 2,4-xylenol, phosphate (3:1) |
| 2,4-xylyl phosphate |
| phosphoric acid, tris(2,4-dimethylphenyl) ester |
| 2,4-dimethylphenol phosphate (3:1) |
| tri(2,4-dimethylphenyl) phosphate |
| tri(2,4-xylenyl)phosphate |
| tris(2,4-xylenyl)phosphate |
| nsc78488 |
| 3862-12-2 |
| nsc-78488 |
| phenol,4-dimethyl-, phosphate (3:1) |
| tris(2,4-dimethylphenyl) phosphate |
| 5tl8h5qk8v , |
| phenol, 2,4-dimethyl-, 1,1',1''-phosphate |
| unii-5tl8h5qk8v |
| tris(2,4-xylenyl) phosphate |
| 0-06-00-00488 (beilstein handbook reference) |
| phenol, dimethyl-, 1,1',1''-phosphate |
| unii-7m08k25q1j |
| ec 246-677-8 |
| 7m08k25q1j , |
| AKOS015899549 |
| SCHEMBL108984 |
| W-110611 |
| tri-2,4-xylylphosphat |
| Q27268543 |
| DTXSID80959466 |
| trixylenylphosphate |
| trixylyl phosphate (txp) |
| CS-0086232 |
| HY-122519 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||